Scilex Holding Company Cost of Revenue
Scilex Holding Company (SCLX) reported Cost of Revenue of $3.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2026-08-14
- Scilex Holding Company cost of revenue for the quarter ending 2026-06-30 was $3.68M, a 12.38% increase year-over-year.
- Scilex Holding Company cost of revenue for the quarter ending 2026-03-31 was $4.45M, a 221.32% increase year-over-year.
- Scilex Holding Company cost of revenue for the quarter ending 2025-12-31 was $2.61M, a 44.28% decline year-over-year.
- Scilex Holding Company cost of revenue for the quarter ending 2025-09-30 was $3.33M, a 11.65% decline year-over-year.
- Scilex Holding Company cost of revenue for fiscal 2025 was $10.60M, a 36.49% decline from fiscal 2024.
- Scilex Holding Company cost of revenue for fiscal 2024 was $16.69M, a 6.43% increase from fiscal 2023.
- Scilex Holding Company cost of revenue for fiscal 2023 was $15.68M, a 45.23% increase from fiscal 2022.
- Scilex Holding Company cost of revenue for fiscal 2022 was $10.80M, a 197.11% increase from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.68M 10-Q · filed 2026-08-14 | $8.12M 10-Q · filed 2026-08-14 | $10.74M derived: sum of 3 quarters · filed 2026-08-14 | $14.07M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $4.45M 10-Q · filed 2026-05-20 | $7.06M derived: sum of 2 quarters · filed 2026-05-20 | $10.39M derived: sum of 3 quarters · filed 2026-05-20 | $13.66M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $5.94M derived: sum of 2 quarters · filed 2026-04-10 | $9.21M derived: sum of 3 quarters · filed 2026-08-14 | $10.60M 10-K · filed 2026-04-10 |
| 2025-09-30 | $3.33M 10-Q · filed 2025-11-14 | $6.60M derived: sum of 2 quarters · filed 2026-08-14 | $7.99M 10-Q · filed 2025-11-14 | $12.68M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $3.27M 10-Q · filed 2026-08-14 | $4.66M 10-Q · filed 2026-08-14 | $9.35M derived: sum of 3 quarters · filed 2026-08-14 | $13.12M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.38M 10-Q · filed 2026-05-20 | $6.08M derived: sum of 2 quarters · filed 2026-05-20 | $9.84M derived: sum of 3 quarters · filed 2026-05-20 | $14.23M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $4.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $8.46M derived: sum of 2 quarters · filed 2026-04-10 | $12.85M derived: sum of 3 quarters · filed 2026-04-10 | $16.69M 10-K · filed 2026-04-10 |
| 2024-09-30 | $3.77M 10-Q · filed 2025-11-14 | $8.16M derived: sum of 2 quarters · filed 2025-11-14 | $12.00M 10-Q · filed 2025-11-14 | $16.52M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $4.39M 10-Q · filed 2025-08-13 | $8.23M 10-Q · filed 2025-08-13 | $12.75M derived: sum of 3 quarters · filed 2025-08-13 | $16.14M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $3.84M 10-Q · filed 2025-05-14 | $8.36M derived: sum of 2 quarters · filed 2025-05-14 | $11.75M derived: sum of 3 quarters · filed 2025-05-14 | $15.93M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $7.91M derived: sum of 2 quarters · filed 2025-03-31 | $12.09M derived: sum of 3 quarters · filed 2025-03-31 | $15.68M 10-K · filed 2025-03-31 |
| 2023-09-30 | $3.39M 10-Q · filed 2025-01-17 | $7.57M derived: sum of 2 quarters · filed 2025-01-17 | $11.16M 10-Q · filed 2025-01-17 | $15.67M derived: sum of 4 quarters · filed 2025-01-17 |
| 2023-06-30 | $4.18M 10-Q · filed 2024-08-13 | $7.77M 10-Q · filed 2024-08-13 | $12.28M derived: sum of 3 quarters · filed 2024-08-13 | $15.89M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $3.59M 10-Q · filed 2024-05-13 | $8.10M derived: sum of 2 quarters · filed 2024-05-13 | $11.71M derived: sum of 3 quarters · filed 2024-05-13 | $13.24M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $8.12M derived: sum of 2 quarters · filed 2024-03-12 | $9.65M derived: sum of 3 quarters · filed 2024-03-12 | $10.80M 10-K · filed 2024-03-12 |
| 2022-09-30 | $3.61M 10-Q · filed 2023-11-14 | $5.14M derived: sum of 2 quarters · filed 2023-11-14 | $6.28M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $1.53M 10-Q · filed 2023-08-11 | $2.67M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $1.14M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $3.63M 10-K · filed 2024-03-12 | |||
| 2020-12-31 | $2.15M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |